Highlights

• Revenue rose 22.9% to $261.7 million in FY26, or 28.4% on a constant-currency basis.

• Underlying net profit after tax grew 24.1% to $144.7 million.

• Underlying EBIT Margin of approximately 74.9% — among the highest in the ASX healthcare sector.

• Approximately $407 million in minimum new contract value across ten new agreements.

• Approximately $141 million in contract renewals across six existing clients.

• Total Dividend lifted 25.5% to 69 cents per share, fully franked.

• Cash and financial Assets of $252.3 million; company remains debt-free.

Pro Medicus Limited (ASX:PME) delivered another standout result in FY2026, reporting revenue of $261.7 million — up 22.9% on the prior year, or 28.4% on a constant-currency basis — alongside underlying net profit after tax of $144.7 million, a 24.1% increase. The Melbourne-based medical imaging software company secured approximately $407 million in minimum new contract value across ten new hospital agreements and $141 million in renewals across six existing clients, extending its dominance of the large US health system imaging market and reinforcing the premium that investors have long placed on the Visage platform.

Sector-Leading Margins Remain the Defining Feature

Pro Medicus's underlying EBIT margin of approximately 74.9% remains one of the highest in the ASX healthcare sector and is a direct reflection of its software-based, transaction-driven Business model. Once a major US health system is contracted and deployed on the Visage platform, rising imaging volumes across that installed base generate incremental revenue at very high margins — a built-in Operating Leverage that competitors reliant on hardware or on-premise installations cannot easily replicate. The debt-free balance sheet, with $252.3 million in cash and financial assets, provides further strategic optionality.

Contract Momentum Extends the US Footprint

The ten new contracts secured in FY26, representing approximately $407 million in minimum value, extended Pro Medicus's reach across the US health system landscape. Six renewals totalling approximately $141 million demonstrated that existing clients are recommitting to the platform at scale. The company continued to lean on its cloud-native archive, viewer and workflow products, and its Research and Development Investment in artificial-intelligence-enabled diagnostic tools positions Visage as a platform that can expand its value to clients beyond the core imaging workflow.

Currency and Reported Profit

Reported net profit jumped approximately 130% to $265.3 million, boosted by non-operating items, making the underlying Earnings figure the cleaner measure of operating performance. The gap between constant-currency and reported revenue growth — 28.4% versus 22.9% — illustrates the meaningful impact of Australian dollar strength on the US-dollar revenue base. On a constant-currency basis, underlying net profit grew approximately 32.5%, underscoring that the operating momentum of the business was stronger than the reported numbers in isolation suggest.

What Investors May Watch

The pipeline of new US health system contracts remains the primary valuation catalyst. Industry gatherings in the radiology calendar are traditional windows for deal announcements and product demonstrations, and management commentary around the artificial-intelligence diagnostic roadmap will attract close attention as investors gauge how Pro Medicus intends to sustain its technology lead. Expansion into adjacencies such as cardiology imaging would represent a meaningful broadening of the addressable market. Rising imaging volumes across the growing installed base provide earnings upside even in periods between major new contract signings.

Risks

Valuation is the overriding risk for Pro Medicus. A stock priced for years of near-flawless execution carries very limited tolerance for a slowdown in contract wins, implementation delays or a compression in the earnings multiple. Client concentration among a relatively small number of large US health systems, the impact of Australian dollar strength on US-dollar revenues, intensifying competition in enterprise medical imaging and AI diagnostics, and regulatory or reimbursement shifts in US healthcare all represent material considerations for investors assessing the stock at current levels.

This article is general information only and does not constitute financial or investment advice.